LIPS islet autoantibody assays in high-throughput format for DASP 2010

Area of Science:

• Biochemistry
• Immunology
• Endocrinology

Background:

• Cost-effective population-based screening for type 1 diabetes requires economical islet autoantibody assays.
• Current methods for detecting autoantibodies like glutamic acid decarboxylase (GAD) and IA2ic are often expensive.

Purpose of the Study:

• To evaluate novel fusion protein constructs for high-throughput islet autoantibody assays using renilla luciferase (Ruc).
• To assess the performance of luciferase-based immunoprecipitation system (LIPS) assays compared to traditional radio-binding assays (RBA).

Main Methods:

• Constructs of GAD-Ruc and IA2ic-Ruc fusion proteins were created and expressed in COS cells.
• Antigen stability and production yield were determined.
• LIPS assays were performed and compared to RBA using serum samples.
• Assay performance was evaluated using Diabetes Autoantibody Standardization Program (DASP) 2010 criteria.

Main Results:

• Sufficient antigen was produced for high-throughput screening (375-535 samples/dish).
• Antigen remained stable for 40-80 days at -80 °C.
• LIPS assays demonstrated favorable signal-to-noise ratios (GAD: 88±24, IA2ic: 219±89) compared to RBA.
• High overall concordance was observed between LIPS and RBA (94.8-95.0%).
• Sensitivity and specificity using DASP 2010 cutoffs were comparable between LIPS and RBA (e.g., GAD LIPS: 80/99%, IA2 LIPS: 72/99%).

Conclusions:

• LIPS assays for GAD and IA2ic islet autoantibodies perform comparably to RBA in the DASP 2010 standardization.
• These LIPS assays offer a potentially more economical method for measuring islet autoantibodies.
• Further optimization of antigen expression and storage could enhance the cost-effectiveness for type 1 diabetes screening.